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Abstract
Vaccination is highly effective in preventing various infectious diseases, whereas the constant threat of new emerging
pathogens necessitates the development of innovative vaccination principles that also confer rapid protection in a case of
emergency. Although increasing evidence points to T cell immunity playing a critical role in vaccination against viral
diseases, vaccine efficacy is mostly associated with the induction of antibody responses. Here we analyze the immunological
mechanism(s) of rapidly protective vaccinia virus immunization using mousepox as surrogate model for human smallpox.
We found that fast protection against lethal systemic poxvirus disease solely depended on CD4 and CD8 T cell responses
induced by vaccination with highly attenuated modified vaccinia virus Ankara (MVA) or conventional vaccinia virus. Of note,
CD4 T cells were critically required to allow for MVA induced CD8 T cell expansion and perforin-mediated cytotoxicity was a
key mechanism of MVA induced protection. In contrast, selected components of the innate immune system and B cell-
mediated responses were fully dispensable for prevention of fatal disease by immunization given two days before
challenge. In conclusion, our data clearly demonstrate that perforin-dependent CD8 T cell immunity plays a key role in MVA
conferred short term protection against lethal mousepox. Rapid induction of T cell immunity might serve as a new
paradigm for treatments that need to fit into a scenario of protective emergency vaccination.
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Introduction
The most effective approach to prevent infectious diseases
caused by viruses is vaccination. During the period of rational
vaccine development, immunogenicity and the efficacy of vaccines
were evaluated in terms of their ability to induce virus-specific
antibodies. More recently however, the focus has shifted to
considering the importance of cellular immune responses. In fact,
vaccine-induced T cell immunity might be crucial to overcome
some viral diseases. Viruses such as influenza virus or HIV are
highly versatile in changing their envelope antigens to escape the
host antibody response. Thus, induction of robust T cell immunity
is believed to be the key to achieving successful immunization
against AIDS, or enabling cross-protective capacities in next
generation influenza vaccines [1–3]. Moreover, T cells are being
recognized as playing an important role in the control of certain
viral infections such as human cytomegalovirus diseases [4,5].
Surprisingly however, there is very limited data about the
contribution of T cell immunity to protection provided by any
licensed viral vaccine. Even today, as in the case of influenza
vaccines, most applications for marketing approval only assess the
potency and efficacy of candidate vaccines using antibody
correlates [6–8]. Moreover, regarding the immunological require-
ments for protective vaccination at times close to viral infection
our knowledge is very limited, perhaps with exception of rabies
where antibodies induced by post exposure vaccination are well
known to prevent the disease and death [9,10].
Vaccinia virus (VACV) is one of the most successful vaccines in
human medicine. Vaccination of live VACV provided efficient
protection against human smallpox, resulting in worldwide
eradication of this devastating infectious disease [11]. Today, the
development of new VACV vaccines is important due to the
increasing emergence of zoonotic diseases caused by orthopox-
viruses [12], and the potential misuse of these viruses as agents of
bioterrorism [13]. One promising VACV vaccine candidate is
based on the highly attenuated virus strain modified VACV
Ankara (MVA) [14–16]. MVA has also been developed as a non-
replicating viral vector to construct experimental recombinant
vaccines against various infectious diseases [17–22]. Immuniza-
tions with MVA in animal models proved highly efficacious when
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compared to conventional VACV vaccines, and elicited antigen-
specific humoral and cellular immune responses [19,23–30].
Mass immunization with VACV during the smallpox eradica-
tion program indicated a critical role for cellular immune
responses, since severe complications could occur in patients with
T cell deficiencies [31–33]. However very little information is
available on the role of cell-mediated immunity in protective
VACV vaccination, although more recent analyses suggest that
humans maintain VACV specific T cells for decades after
vaccination [34–36].
There is more historical evidence correlating protection against
smallpox with VACV neutralizing antibodies [37,38]. Indeed,
recent studies with orthopoxvirus challenge infections in animal
models support the supposed protective role of antibody responses
elicited by VACV immunization [39,40]. Interestingly, very
comparable levels of VACV neutralizing antibodies are found
after MVA or conventional VACV (Dryvax) immunization [27].
In addition, MVA immunization can induce VACV specific
antibody responses slightly earlier than conventional VACV
(Elstree/Lister or Dryvax) in mice or non-human primates
[39,41]. Moreover, VACV vaccination of mice and macaques
can result in full protection from lethal disease if administered
shortly before or even after infection with virulent orthopoxviruses
[39,41–43]. In such cases rapid protection was associated with
relatively high doses of vaccine, which may elicit earlier induction
of antigen-specific immunity [39,41,43].
Here, we used ectromelia virus (ECTV) infections of mice,
probably the best surrogate animal model for human smallpox.
Our aim was to analyze the immunological mechanism(s) of the
early protective capacity conferred by MVA immunization.
Surprisingly, we found that rapid protection against lethal systemic
poxvirus disease, as mediated by vaccination with MVA or
conventional VACV, is solely dependent on the cellular adaptive
immune response with an important role of CD4 and CD8 T cells,
and perforin mediated cellular cytotoxicity. In contrast, the
humoral response seems to be fully dispensable in providing early
protection. Our data clearly demonstrate that T cell immunity
plays a key role in the protective capacity of vaccination with a
gold standard live viral vaccine. In general, the rapid induction of
robust T cell responses might be of great importance for
developing vaccines that need to meet the demands of protective
emergency vaccination.
Results
Local immune responses to MVA
Intranasal (i.n.) application of MVA vaccine can rapidly induce
robust protection against lethal respiratory orthopoxvirus infec-
tions [41,43]. However, the mechanisms of protective immunity
still need to be elucidated. In particular, only limited information
about local immune responses in the respiratory tract is available.
Recent data suggest that in the vaccinated host MVA is recognized
via multiple sensor pathways, which results in the activation of
innate immunity, including the synthesis of type I interferons (IFN)
and chemokines. These innate responses will trigger attraction of
immune cells to the site of immunization, which might be
responsible for the rapid development of protective adaptive
immunity [44–47].
In agreement with these data, our histopathological analysis of
C57BL/6 mice two days after i.n. inoculation with MVA revealed
a marked peribronchiolar and perivascular infiltrate of leukocytes
in the infected lung sections compared to lung sections of mock
inoculations with PBS (Figure S1). Histopathological inspection at
higher magnification clearly showed neutrophil granulocytes and
macrophages among the infiltrate (Figure S2). We further
characterized the infiltrated leukocytes by bronchoalveolar lavages
(BAL) at different time-points after i.n. administration of MVA.
During the first 72 hours post infection (h p. i.) the infiltrates
mainly consisted of monocytes, dendritic cells (DC), neutrophils,
and NK cells (Figure S3), suggesting that the lung environment is
highly favorable for antigen presentation and induction of
adaptive responses. Indeed, we were able to observe increasing
amounts of T and B cells in the BAL fluids of MVA exposed
animals at later time points of infection (Figure 1). We detected
CD4 and CD8 positive (+) T cells starting 48 h p. i., which
increased in numbers to 20.5% (CD4+) and 41.5% (CD8+) of total
BAL cells on day 6 p. i. (Figure 1A). To monitor VACV-specific
CD8+ T cell responses we used the Kb-restricted immunodomi-
nant determinant TSYKFESV from the VACV B8 protein being
referred to as B8R20–27 [48] The immunodominance of B8R20–27
has been shown to be conserved for various orthopoxviruses
including ECTV and VACV, and even in mice lacking IFN-c or
perforin [48,49]. In MVA, the B8R open reading frame lacks
some nucleotides compared to the B8R gene sequence of
conventional VACV strain Lister/Elstree and encodes for a
truncated B8 polypeptide. Importantly, MVA is expected to
produce a fully conserved N-terminal part of the B8 protein
containing the peptide epitope B8R20–27 and very similar
expression levels of this specific B8R product were found for
MVA and conventional VACV strain Elstree (Figure S4). When
performing intracellular cytokine staining for interferon gamma
(IFN-c) we found proportionally high numbers of activated VACV
(B8R20–27 epitope)-specific CD8+ T cells in BAL liquids by day
5 p. i., but comparatively lower numbers of VACV-specific CD8+
T cells in the spleen. This pattern was also observed by day 7 p. i.,
with about three times higher numbers of specific CD8+ T cells in
BAL than in the spleen (Figure 1B). When determining B220+
CD3- B cells in the BAL cell population we could detect the
presence of substantial numbers of B cells at day 6 p. i. (Figure 1C).
Additionally, we also monitored for the presence of MVA-specific
Author Summary
Prophylactic use of vaccinia virus allowed eradication of
human smallpox, one of the greatest successes in
medicine. However there are concerns that variola virus,
the infectious agent of smallpox, may be used as
bioterroristic weapon and zoonotic monkeypox or cowpox
remain threatening infections in humans. Thus, new
developments of safe and rapidly protecting orthopox-
virus-specific vaccines have been initiated. The candidate
vaccine modified vaccinia virus Ankara (MVA) was recently
shown to protect against lethal systemic poxvirus disease
even when applied shortly before or after infection of mice
with ectromelia virus, the probably best animal model for
human smallpox. Surprisingly, little is known about the
protective mechanism of early immune responses elicited
against orthopoxvirus infections. Here, we used the
mousepox model to analyze the immunological basis of
rapidly protective MVA vaccination. In contrast to common
understanding of orthopoxvirus vaccine efficacy relying
mainly on antibody mediated immunity, we observed
unimpaired protection also in absence of B cells.
Surprisingly, rapid protection by vaccination with MVA or
conventional vaccinia virus was solely dependent on T
cells, irrespective of the route of injection. Thus, our study
suggests a key role for T cell immunity in rapidly protective
immunization against orthopoxviruses and potentially
other infectious agents.
Rapid Protection against Mousepox Requires T Cells
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antibodies in BAL fluids at days 3, 6 and 8 after i.n. inoculation
with MVA. We initially detected low levels of MVA-specific IgG
by day 6, but antibody levels increased by day 8 p. i. (Figure 1D).
Altogether, these results indicate that early local immune
responses induced after in vivo MVA inoculation are characterized
by powerful innate responses, including the migration of massive
amounts of innate immune cells to the site of infection. Moreover,
antigen-specific cellular and humoral immune responses were also
rapidly induced within the respiratory tract, suggesting that the
rapid protection provided by MVA may be due to a close interplay
between innate and adaptive immunity.
Rapidly protective MVA immunization in the absence of
NK cells or TLR, RIG-I or Mda5 mediated signaling
To elucidate the role of selected components of the innate and
adaptive immune system on the rapid protection, we performed
MVA immunization experiments in the C57BL/6 mouse/ECTV
challenge model [41]. Briefly, we i.n. inoculated mice with 108
PFU MVA two days before a lethal respiratory infection with
ECTV (200 PFU corresponding to 36LD50) (Figure 2A). This
immunization fully protected the animals from disease and death
after ECTV infection (P = 0.0001). In contrast, unvaccinated
control mice started to show signs of morbidity (body weight loss)
at about 6 days after challenge infection, and all died within 11
days (Figure 2A). Moreover, analysis of the viral loads in liver and
lungs of vaccinated animals demonstrated full viral clearance at
day 21 post infection (data not shown).
Recognition of invading pathogens by host cells is considered
essential for activating innate and adaptive immune responses.
Indeed as mentioned above, we confirmed a strong early
activation of local innate immunity upon intranasal immunization
(Figure S3). Also in previous experiments with IFNAR2/2 mice
lacking the type I IFN receptor, we had found a somewhat lesser
protective capacity of MVA vaccination [41], indicating a role of
sensing pathways that mediate recognition signals. This sensing is
mainly achieved via Toll-like receptors (TLRs) and retinoic acid-
inducible gene-I (RIG-I)-like receptors (RLRs) [44].
Here, upon MVA i.n. inoculation of C57BL/6 mice we did
indeed detect interleukin-6 (IL-6) and interferon-alpha (IFN-a) in
BAL fluids within 6 hours and 24 hours p. i. (Figure S5) suggesting
TLR and RLR dependent immune activation. We therefore
performed the MVA immunization/ECTV challenge experiments
in MyD88/Trif2/2 mice lacking TLR signaling (Figure 2B), and
IPS2/2 mice lacking RLR signaling (Figure 2C). Clearly, the
Figure 1. Intranasal vaccination of mice rapidly induces cellular and humoral adaptive immune responses in the respiratory tract.
(A) Numbers of total CD3+ CD8+ (CD8+) and CD3+ CD4+ (CD4+) T cells in bronchoalveolar lavage (BAL) (mean pooled from three mice) at the
indicated time points after inoculation with MVA (filled symbols) or mock vaccine (empty symbols). (B) Intracellular cytokine staining for gamma
interferon (IFN-c) in CD8+ CD62Llow spleen cells from individual mice (n = 6), or BAL cells pooled from 3 to 5 mice (mean 6 SD from three
independent experiments) stimulated with VACV specific B8R20–27 or control peptides (LacZ876) at 3, 5 and 7 days post MVA immunization. (C)
Numbers of total B220+ CD32 B cells in BAL (mean pooled from three mice) at indicated time points after inoculation with MVA (filled symbol) or
mock (empty symbol) vaccine. (D) MVA specific IgG levels in BAL fluids pooled from three mice at indicated time points after inoculation with MVA
(filled bars) or mock (empty bars) vaccine. The graph depicts the OD 490 nm measured by ELISA at 1:10 dilution of BAL fluid. All BAL data represent
the results from two independent experiments.
doi:10.1371/journal.ppat.1002557.g001
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absence of either TLR or RLR signaling had no influence on the
protective capacity of immunization with MVA (P = 1), confirming
that several innate signaling cascades and innate immune cells can
respond to MVA immunization. These likely compensate for each
other in mediating sufficient immune activation to provide rapid
protection.
NK cells are known to play a major role in mediating resistance
to ECTV infections in mice [50–52] and indeed, we found NK
cells infiltrating the lungs of mice early after i.n. MVA inoculation
(Figure S3D). To examine the role of NK cells in rapid protection
we removed NK cells by antibody-mediated depletion. Absence of
NK cells on the day of MVA immunization (day -2) was confirmed
by FACS analysis (Figure S6A). We observed no difference in the
protective capacity acquired by NK cell-depleted mice compared
to controls (Figure 2D; P = 1), indicating that the protective effect
of short-term immunization with MVA is fully maintained even in
the absence of NK cells.
Rapidly protective MVA immunization in the absence of
B cells
Previous work had already indicated that adaptive immunity
contributes to MVA-induced protection against lethal ECTV
infection [41]. Furthermore, passive immunization with vaccinia
immune globulin around the day of infection fully protects mice
against lethal mousepox [53], indicating that antibodies are the
important players in adaptive immunity. Indeed, we showed above
that specific antibodies are found in the respiratory tract early after
intranasal inoculation with MVA (Figure 1D). To further analyze
the role of antibody responses we performed experiments to assess
the rapid protective capacity of MVA vaccination in RAG-12/2
mice lacking mature T and B cells, and in B cell-deficient mMT
mice [54]. Confirming previous data, vaccinated RAG-12/2 mice
(Figure 3A) all succumbed to the ECTV challenge infection,
confirming the importance of adaptive responses in rapid
protection. However, MVA immunization robustly protected B
cell-deficient mice from disease and death (Figure 3B; P,0.0001).
For further confirmation, we tested an alternative strain of B cell-
deficient mice [55], JHT, where we also found full protective
capacity of MVA immunization (Figure S7). Thus surprisingly, B
cells and antibodies seem to be dispensable for this rapidly induced
protective immunity.
Rapid protection requires CD8+ and CD4+ T cells
The data so far indicated that T cells might play a crucial role in
short-term protective immunity. Analysis of VACV specific CD8+
T cell responses elicited by MVA immunization in JHT mice
showed levels of VACV specific CD8+ CD62low T cells
comparable to those induced in C57BL/6 wt mice (Figure S8).
Figure 2. Unimpaired protective capacity of MVA immunization in mice lacking selected key adaptors of innate signaling
pathways, or natural killer (NK) cells. (A) C57BL/6 mice (wt), (B) MyD88/Trif2/2, (C) IPS2/2 knock-out mice, or (D) NK cell depleted C57/BL/6 mice
were challenged with 36LD50 ECTV two days after MVA immunization (#), with mock-challenged (&), and mock-vaccinated (m) animals as controls.
In all experiments weight loss of individual mice was monitored daily (n = 2 to 6 per group). +indicate the individual time of death. Error bars indicate
SEMs, and the numbers of surviving/total animals are given in parentheses. Statistical significance of differences between groups is indicated by * for
p-value,0.05, ** for p-value,0.01 and *** for p-value,0.001.
doi:10.1371/journal.ppat.1002557.g002
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Figure 3. Protective immunization depends on adaptive immune responses but not on the presence of B cells. (A) RAG-12/2 mice
lacking mature B and T cells, or (B) B cell-deficient mMT mice were i.n. immunized with MVA (#) two days before 36LD50 ECTV challenge. Mock-
challenged (&) and mock-vaccinated (m) mice served as controls. In all experiments weight loss of individual mice was monitored daily (n = 3 to 6 per
Rapid Protection against Mousepox Requires T Cells
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Thus, B cell-deficient mice are still able to mount specific T cell
responses, further corroborating that T cell responses might be
important for short-term protection.
Thus, we depleted C57BL/6 mice of CD4+ T cells, CD8+ T
cells or both T cell subsets by i.p. injection of specific antibodies,
and confirmed successful depletion by FACS analysis at the time
point of MVA immunization (day 0) and at day 7 after
vaccination (Figure S6B,C; data not shown). Control C57BL/6
mice were again fully protected by MVA immunization two
days prior to the lethal respiratory challenge infection with
ECTV (Figure 4A). In contrast, vaccinated mice depleted of
CD8+ T cells, or both T cell subsets (Figure 4B,C) succumbed to
ECTV infection, with similar disease pattern and time to death
as compared to unvaccinated animals. On the other hand,
depletion of CD4+ T cells (Figure 4D) prior to MVA
immunization resulted in delayed onset of disease, since the
start of striking body weight loss occurred about six days after
the onset of symptoms in unvaccinated controls. Nevertheless,
CD4+ T cell depletion in immunized animals also resulted in
100% mortality within 21 days post challenge. These data
clearly suggested that both CD4+ and CD8+ T cells are
required to rapidly protect mice by MVA vaccination. To assess
the need for CD4+ T cells in some more detail, we analyzed
CD4-depleted C57BL/6 mice for defects in mounting VACV-
specific antibodies or CD8+ T cells following MVA immuniza-
tion. Lack of CD4+ T cells resulted only in a minor reduction of
IgG antibody responses as revealed by ELISA testing of sera at
day 21 post vaccination with 108 PFU MVA (i.n.). The CD4 cell
depleted mice were clearly able to mount levels of VACV-
specific antibodies (mean titer of pooled sera 1280) that were
just about two fold lower than responses obtained in control
mice (data not shown). To study the impact of CD4+ T cell
depletion on MVA induced CD8+ T cell responses we
monitored for the expansion of endogenous CD8+ T cells
specifically recognizing the B8R20–27 epitope (TSYKFESV) by
FACS analysis using a TSYKFESV-Kb pentamer (ProImmune)
(Figure 5). Upon inoculation of C57BL/6 mice with 26105 PFU
MVA, B8R-specific T cells massively expanded and reached a
maximum of approximately 20% of total CD8+ T cells at day 6
after infection. On the contrary, MVA-vaccinated CD4+
depleted mice showed a significantly reduced CD8+ T cell
expansion reaching less than 10% of total CD8+ T cells
(Figure 5A). This data suggested that CD4+ T cells seem to play
an important role in regulating the strength of the MVA
induced CD8- T cell response.
To further confirm the relevance of T cell immunity in rapid pro-
tection by MVA immunization we adoptively transferred naı¨ve
CD3+ splenocytes, which comprise mainly T cells, into RAG-12/2
mice. After two days these mice were vaccinated with 108 PFU
MVA and challenged two days later with ECTV. Indeed, the
transfer of T cells prior to vaccination was fully sufficient to pro-
tect RAG-12/2 mice against lethal infection, whereas control
RAG-12/2 mice all died despite MVA immunization (Figure 6;
P = 0.0003). Interestingly, control RAG-12/2 showed a slight delay
in onset of disease upon MVA immunization (Figure 3A, Figure 6)
which cannot be observed in mice depleted of CD4+ and CD8+ T
cells (Figure 4). This effect may be due to elevated NK cell numbers
in non-lymphoid tissue of RAG-12/2 mice [56] that might
transiently compensate for the lack of T and B cells.
Cytotoxic effector molecule perforin is essential for rapid
protection
T cells seemed to play a dominant role in rapid protection
mediated by MVA. CD4+ and CD8+ T cells exert different
effector functions to control infections. CD4+ T cells primarily
activate other immune cells like B cells and macrophages through
expression of cytokines [57–59] and they are also recognized as
being crucially involved in the activation of antigen-specific CD8+
T cells [60]. In contrast, CD8+ T cells can directly kill infected
cells which is mediated by the release of cytotoxic granules
containing notably perforin and granzymes. Furthermore, studies
showed that cell-mediated cytotoxicity and especially perforin is
important for recovery from ECTV infection [61,62]. To analyze
the role of perforin mediated cellular cytotoxicity in rapid
protection, we vaccinated perforin deficient mice (Prf2/2) i.n.
with 108 PFU MVA two days before a lethal challenge infection
with ECTV. In contrast to wt mice, Prf2/2 mice were not
protected, developed severe disease and all mice succumbed to
ECTV infection until day 18 post infection (Figure 7A).
Correspondingly, we detected high levels of virus in lung and
liver of MVA vaccinated Prf2/2 mice at the time point of death,
while vaccinated wt mice had cleared the virus at the end of the
experiment (21 dpi) (Figure 7B). Nevertheless, livers of MVA
immunized Prf2/2 mice contained reduced virus loads in
comparison to mock vaccinated Prf2/2 controls. This observation
appeared to correlate with the somewhat prolonged course of
disease in vaccinated animals (not statistically significant) and
might be the consequence of innate or humoral adaptive immune
responses including the possible contribution of type I and/or type
II interferons. Histopathologic examination revealed multiple
randomly located foci of necrosis and inflammation in the liver
of vaccinated and ECTV challenged Prf2/2 mice (Figure 7C,
upper panel). These lesions were characterized by hepatocytic
necrosis and infiltration by macrophages and lymphocytes.
However, MVA immunized wt mice had no necrotic and
inflammatory lesions in liver tissues (Figure 7C, lower panel).
Thus, the availability of the cytotoxic effector protein perforin was
essential to maintain the protective capacity of MVA immuniza-
tion suggesting the induction of T cell mediated cytotoxicity as key
mechanism of protective immunity.
T cell-dependent rapid protection after conventional
smallpox vaccination
Intranasal immunizations with VACV are being increasingly
investigated as a means to induce immunity associated with the
respiratory tract or mucosal tissues. Such applications might be
useful in swift mass vaccinations to help overcome major
challenges in public health interventions. However, almost all
immunizations with VACV in humans, e.g. with the widely used
smallpox vaccine strains Lister/Elstree and New York City Board
of Health, involved intradermal (i.d.) application through
scarification [11]. Clinical uses of MVA-based vaccines routinely
choose intramuscular (i.m.) or subcutaneous applications. To
elucidate the role of T cells in the rapid protective capacity
induced by more conventional vaccination, we again depleted
C57BL/6 mice of CD4+ and CD8+ T cells by specific antibodies
at the time point of immunization (Figure S6B,C). The rapid
protective capacity of i.n. MVA immunization was compared with
group). +indicate the individual time of death. Error bars indicate SEMs, and the numbers of surviving/total animals are given in parentheses. Data are
representative of two or three similar experiments. Statistical significance of differences between groups is indicated by * for p-value,0.05, ** for p-
value,0.01 and *** for p-value,0.001.
doi:10.1371/journal.ppat.1002557.g003
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i.m. MVA immunization using 108 PFU (Figure 8A,B), as well as
with i.d. vaccination with 106 PFU of VACV strain Elstree
(Figure 8C). Previous studies had confirmed the protective
capacity of this lower-dose immunization using the fully
replication competent VACV Elstree [41]. As expected, control
C57BL/6 wt mice were fully protected by vaccination two days
prior to the lethal respiratory challenge infection with ECTV
(p = 0.006 for MVA i.n.; p = 0.0011 for MVA i.m.; p = 0.005 for
VACV Elstree). In sharp contrast, all vaccinated, T cell-depleted
animals succumbed to ECTV infection irrespective of vaccination
by MVA or VACV Elstree strains or the different routes of
immunization. Additionally, the morbidity profiles of T cell-
depleted, vaccinated animals were comparable to mock-vaccinated
controls (p = 1 for MVA i.n.; p = 0.3489 for MVA i.m.; p = 1 for
VACV Elstree i.d.). Furthermore, the protective capacity of MVA
vaccination was lost when i.m. inoculating heat-inactivated MVA
doses (corresponding to 108 PFU) (Figure S9) suggesting the need
to immunize live MVA vaccine. These data clearly suggest an
essential general requirement for both CD8+ and CD4+ T cells in
rapidly protective immunization against fatal mousepox.
Discussion
Vaccination is still the most successful approach to prevent viral
diseases. The recent threats of suddenly emerging severe infectious
diseases, e.g. caused by severe acute respiratory syndrome
coronavirus, West Nile virus, or avian influenza virus, demonstrate
the need for new vaccines ready to use in an immediate public
health response. Previous studies in animal models for preventing
fatal orthopoxvirus disease had shown that immunizations with
MVA or conventional VACV could provide protection in a time
window close to lethal infection [39,41,43]. The purpose of the
present study was to determine the immunological mechanisms
mediating this rapid protective capacity of MVA vaccination in an
orthopoxvirus infection model. Previous studies in the mousepox
model had shown that pre- and post-exposure protection can be
achieved, and suggested that the induction of adaptive immune
responses was essential [41,42]. Post-exposure immunizations, in
particular when given at later times (e.g. 2 days post ECTV
infection), can not prevent the onset of severe mousepox disease
[41]. However, this feature clearly hampers the definition of
immune correlates for MVA vaccine mediated rapid protection
(our unpublished data) [63]. In contrast, MVA vaccination two
days prior to lethal ECTV challenge allows for solid protection
also against the onset of morbidity. Therefore, we chose the pre-
exposure immunization model for this study.
The present work was carried out in C57BL/6 mice deficient in
various components of the innate or adaptive immune system,
exposed to a lethal respiratory infection with ECTV administered
two days after immunization. Immunization and challenge of
Figure 4. T cells are required for rapidly protective immunization. (A) C57BL/6 mice (wt), (B) mice depleted of CD4+ and CD8+ T cells, (C)
depleted of CD8+ T cells, or (D) depleted of CD4+ T cells were challenged with 36LD50 ECTV two days after MVA immunization (#), with mock-
challenged (&) and mock-vaccinated (m) mice as controls. In all experiments weight loss of individual mice was monitored daily (n = 2 to 6 per
group). +indicate the individual time of death. Error bars indicate SEMs, and the numbers of surviving/total animals are given in parentheses. Data are
representative of two or three similar experiments. Statistical significance of differences between groups is indicated by * for p-value,0.05, ** for p-
value,0.01 and *** for p-value,0.001.
doi:10.1371/journal.ppat.1002557.g004
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normal C57BL/6 mice served as controls to determine the degree
of protection, as monitored by disease symptoms, body weight loss
and survival. Moreover, intranasal vaccination of fully immune
competent mice allowed us to assess the quality and kinetics of
immune responses elicited at the primary site of immunization.
Previous studies had suggested that VACV and MVA are
recognized via multiple host-sensing pathways, including TLRs,
RLRs and NOD-like receptors (NLRs) [44,64]. Furthermore,
MVA infection induces pro-inflammatory cytokines such as TNF-
a [44,65], type I interferons [14,47,66] and chemokines like CCL2
that attract leucocytes to the site of inoculation [46]. At 24 to
48 hours after i.n. MVA inoculation we found prominent
infiltrations of immune cells in the lungs of immunized mice.
We also detected significantly increased amounts of the pro-
inflammatory cytokines IL-6 and IFN-a in BAL fluids, which
correlate with efficient activation of innate responses in the
respiratory tract.
Previous analysis of systemic adaptive immune responses had
shown that MVA vaccination elicits strong CD8+ and CD4+ T
cell responses with a T-helper type 1 (Th1)-dominant profile
[25,30,67,68] as well as orthopoxvirus-specific antibodies
[25,68,69]. Here we demonstrate that antigen-specific immune
responses can be detected in the respiratory tract at early times
after immunization. Of note, we found two to three-times higher
numbers of IFN-y producing VACV (B8R20–27) specific CD8+ T
cells in lungs than in spleens. This supports the hypothesis that
early local priming of antigen-specific T cells may occur, which is
possibly associated with MVA-induced formation of bronchus-
associated lymphoid tissue [45]. The rapid expansion of virus-
specific CD8+ T cells is further supported by the recent finding of
Chaudhri and coworkers that antigen-specific T cell receptors can
be transferred and shared among CD8+ T cells to enhance the
anti-viral response upon orthopoxvirus infection [70].
Previous work in IFNAR2/2 mice had indicated a partial
influence of type I IFN in rapid protection mediated by MVA
vaccination [41]. Here we show that the protective capacity of
MVA immunization was fully maintained in MyD88/Trif2/2 and
IPS2/2 mice that are deficient in TLR and RLR signaling
pathways controlling the expression of type I IFN. Nevertheless, it
cannot be excluded that other innate recognition pathways are
involved in mediating a type I IFN response to MVA. Thus it
seems likely that due to versatile recognition of MVA, signaling
pathways can compensate for each other to provide the innate
responses essential for developing protective adaptive immunity.
In particular, further study of the possible contribution of type I
IFN in rapidly protective MVA immunization seems promising
because concomitant type I interferon receptor triggering on T
cells and DC has been recently shown to allow for optimal
expansion of MVA induced CD8 T cell responses [71].
NK cells are part of the cellular innate immune response and
recent work established their key role in host specific control of a
primary ECTV infection [51,52]. Interestingly, we found here that
depletion of NK cells did not influence the rapid protective
capacity of MVA vaccination. This observation already indicated
differences in the modes of immune defense when comparing
rapidly protective primary immunization, protection against
secondary infection, and overcoming a primary ECTV infection.
This latter scenario is well characterized in C57BL/6 mice that
resist foot-pad infections known to be lethal in more susceptible
mouse strains. This primary resistance was shown to mainly
depend on the presence of NK cells and T cells. Nevertheless, B
cells are essential for complete virus clearance and recovery
[50,52,72,73]. In contrast, protective immunity against secondary
infections, elicited by primary infection or conventional vaccina-
tion, is dominated by antibody responses [23,27,40,74–76].
Recovery from secondary ECTV infection was demonstrated to
rely on a more rapid recall antibody response than in primary
infection, whereas secondary recall CTL responses were not
altered compared to primary CTL responses [77]. Nevertheless,
memory CD8+ T cells are known to prevent viral spread by killing
viral targets in the draining lymph nodes and thus are also
important in controlling secondary ECTV infections [78]. Thus,
the antibody memory response seems to be mandatory for long-
term protective immunity against orthopoxvirus infections espe-
cially in controlling virus persistence while T cell responses might
be more important to prevent viral spread.
Previous immunization experiments in T and B cell deficient
RAG-12/2 mice had already indicated that adaptive responses are
indispensible to achieving rapidly protective immunity [41,42].
We also suspected a key role of humoral immunity in rapidly
protective immunization, since MVA can induce antibody
responses much faster than conventional VACV [39,41]. More-
over vaccinia immune globulin is effective in post-exposure
Figure 5. CD4+ depleted mice show a reduced CD8+ virus-
specific T cell expansion upon MVA immunisation. C57BL/6 mice
were treated twice with 250 mg anti-CD4 Ab (GK1.5 Harlan) two and
one day prior to immunization with 26105 pfu MVA. As control
untreated mice were immunized with 26105 pfu MVA. (A) The
frequency of expanded B8R-specific CD8+ T cells in control mice (black)
and CD4-depleted mice (white) was monitored within the blood at
different time points post MVA immunization. (B) CD4+ T cell depletion
efficiency was monitored at the day of immunization by flow cytometry
of blood samples. CD4+ and CD8+ T cells within CD3+ population of
blood lymphocytes are shown from representative mice. (C) CD4+ T cell
depletion efficiency at 6 dpi, the day of maximal T cell expansion, was
calculated as % CD4+ of total peripheral blood lymphocytes (PBL). Data
shown are pooled from two independent experiments with n = 5 mice
per group. Statistical significance is shown by *** p.0.0001 using two-
tailed t-test.
doi:10.1371/journal.ppat.1002557.g005
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treatment of lethal orthopoxvirus infections [28,53,79]. However
surprisingly, we found that vaccinated B cell-deficient mice were
still fully protected. MVA immunization prevented the onset of
any detectable disease in B cell deficient animals for at least four
weeks following respiratory challenge infection. This is remarkable
because in this intranasal infection model (at low dosage of
200 PFU ECTV) normal C57BL/6 mice (not vaccinated) suffer
from severe systemic mousepox and succumb within 10 to 14 days
after challenge [80]. It is worth noting, however, that ECTV can
persist for several months without any signs of disease in naı¨ve
C57BL/6 mice following footpad inoculation and, in infected B
cell deficient animals, the onset of symptoms must not occur until
very late in infection [72,73]. Yet, on the contrary, depletion of
CD4+ or/and CD8+ T cells in C57BL/6 mice completely
abrogated the protective capacity of immunization against the
respiratory ECTV challenge. Moreover, the need for T cell-
mediated immunity was underlined by the transfer of naı¨ve
CD3+ T cells into RAG-12/2 mice, which supported protective
vaccination of these immunocompromised animals against lethal
ECTV challenge. Furthermore, depletion of CD4+ T cells was
sufficient to inhibit the protective effect of MVA immunization,
although we observed clearly delayed onset of morbidity. This
observation may be best explained by an essential role of T helper
cells in mediating efficient clearance of virus by CD8+ T cell
activity. Importantly, this possibility is clearly supported by our
demonstration that depletion of CD4+ T cells significantly
reduced the in vivo expansion of endogenous VACV-specific
CD8+ T cells. Similarly, CD4+ T cells have been found essential
for maintaining a robust or protective cytotoxic T cell memory
response upon vaccination with recombinant VACV expressing
lymphocytic choriomeningitis virus glycoprotein, or upon infection
of mice with Listeria monocytogenes bacteria [81,82,83] The
possibility that clearance of ECTV cannot be accomplished
because of the absence of T helper cell dependent antibody
responses appears unlikely in the view of the fact that CD4-
depleted animals still mounted substantial levels of VACV-specific
antibodies. Moreover, we clearly demonstrated the essential need
for the direct cytotoxic effector function of CD8+ T cells to
mediate rapid protection as the absence of perforin completely
abrogated the protective capacity of immunization. Nonetheless,
we observed reduced levels of ECTV also in the livers of
vaccinated Prf2/2 mice indicating that MVA induced innate
responses might have modulated the course of infection. This
hypothesis is in agreement with previous findings of an early
enhanced production of chemokines and cytokines after in vivo
inoculation of MVA but not other strains of VACV [46,84].
Importantly, we confirmed the necessity of T cells in rapid
protection not only with MVA immunizations via the intramus-
cular route, but also conventional scarification using VACV strain
Elstree vaccine. These data suggests that the need for T cell-
mediated immunity is independent of the vaccination route or
vaccine strain used. Moreover, this indicates a general require-
ment of T cells for rapidly protective immunizations against
orthopoxvirus infections, and maybe also against other infectious
Figure 6. Transfer of naı¨ve CD3+ T cells into RAG-12/2 mice restores rapid protection by MVA vaccination. Vaccinated RAG-12/2 mice
(e) or vaccinated RAG-12/2 mice that received naı¨ve CD3+ spleen cells two days before immunization with MVA (#) were challenged with 36LD50
ECTV two days after vaccination. Groups of RAG-12/2 mice that received naı¨ve CD3+ spleen cells served as mock-challenged (&) or mock-vaccinated
(m) controls. In all experiments weight loss of individual mice was monitored daily (n = 3 to 6 per group). +indicate the individual time of death. Error
bars indicate SEMs, and the numbers of surviving/total animals are given in parentheses. Data are representative of two similar experiments.
Statistical significance of differences between groups is indicated by * for p-value,0.05, ** for p-value,0.01 and *** for p-value,0.001.
doi:10.1371/journal.ppat.1002557.g006
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diseases that necessarily fit a scenario of emergency vaccination. In
addition, we present here an outstanding experimental model for
immunizations with a live viral vaccine suitable for use in humans,
where protective vaccination strictly depends on T cell responses.
Future work with this model should help in the development of
new vaccines eliciting more effective T cell mediated immunity.
Materials and Methods
Ethics statement
This study was carried out in strict accordance with German
regulations for animal experimentation (German Animal Welfare
Act). All experimentations were approved by the Government of
the State of Hesse (Paul-Ehrlich-Institut, Permit Numbers 107/65,
107/67, 107/82), the Government of Upper Bavaria (University of
Munich LMU, Permit Number 59.10) and the Niedersa¨chsische
Landesamt fu¨r Verbraucherschutz und Lebensmittelsicherheit
(LAVES). All intranasal inoculations were performed under
ketamine/xylazine anesthesia, and all efforts were made to
minimize suffering of infected animals.
Cells and viruses
Monkey BS-C-1 (ATCC CCL-26), murine NIH3T3 (ATCC
CRL-1658), human monocytic THP-1 (German Collection of Cell
Culture DSMZ, Braunschweig, Germany) and chicken embryo
fibroblast (CEF) cells were used and routinely maintained as
previously described [25]. [46]. Plaque purified Ectromelia virus
(ECTV) strain Moscow (ATCC VR-1374, kindly provided by
Mark L. Buller, St. Louis University School of Medicine, St. Louis,
Missouri, USA) was propagated on BS-C-1 cells. Modified
vaccinia virus Ankara (MVA) (clonal isolate F6) [16,22] was
Figure 7. Protective capacity of vaccination is lost in absence of the cytolytic effector molecule perforin. (A) C57BL/6 mice (wt, open
symbols) and perforin deficient C57/BL/6 mice (Prf2/2, closed symbols) were challenged with 36LD50 ECTV two days after MVA immunization (N),
with mock-challenged (&), and mock-vaccinated (m) animals as controls. In all experiments weight loss of individual mice was monitored daily (n = 4
to 6 per group). +indicate the individual time of death. Error bars indicate SEMs, and the numbers of surviving/total animals are given in parentheses.
Data are representative of two similar experiments. Statistical significance of differences between groups is indicated by * for p-value,0.05, ** for p-
value,0.01 and *** for p-value,0.001. (B) At the timepoint of death (day 9 p.i. for Prf2/2 mock-vaccinated, day 12 p.i. for Prf2/2 MVA and wt mock-
vaccinated) or at the end of the experiments (day 21 p.i. for wt MVA) lung and liver were removed, homogenized, and the amount of virus was
determined by plaque assay (n = 2 to 3 animals per group). Error bars indicate SEMs and data are representative of at least two independent
experiments. n.d.: not detectable. (C) Histopathologic examination of liver tissue from MVA vaccinated and ECTV challenged Prf2/2 (upper panel) or
wt mice (lower panel) at day 12 p.i.. Tissues were stained with hematoxilin and eosin (HE) and evaluated by light microscopy. Micrographs show
representative areas of liver tissue. A typical focus of necrosis and inflammation in the liver of the Prf2/2 mouse is visible in the center of the upper
micrograph.
doi:10.1371/journal.ppat.1002557.g007
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Figure 8. T cell responses are generally required for rapid protection by immunizations with vaccinia virus. C57BL/6 mice (#) or
C57BL/6 mice depleted of CD4 and CD8 T cells (e) were (A) vaccinated with 108 PFU MVA intranasally (i.n.), or (B) intramuscularly (i.m.), or (C) by
scarification (i.d.) with 106 PFU VACV Elstree (i.d.) at two days before the 36LD50 ECTV challenge infection. Mock-challenged (&) and mock-
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propagated on CEF cells. Viral titers were determined by plaque
assay and titrated in plaque forming units (PFU) as previously
described [25,85].
Mice
Female C57BL/6N mice (6–10 weeks old) were purchased from
Charles River Laboratories (Sulzfeld, Germany). C57BL/6J-Igh-
6tm1Cgn mice (mMT, immunoglobulin heavy chain 6 deficient [heavy
chain of IgM]) [54] and C57BL/6-Prf1tm1Sdz/J mice (Prf2/2,
perforin deficient) [81]. were purchased from The Jackson
Laboratory. C57BL/6J-Rag1tm1Mom mice (RAG-12/2, mice homo-
zygous for the Rag1tm1Mom mutation produce no mature T cells or B
cells) [86], C57BL/6 MyD882/2 TRIF2/2 mice [47,87], C57BL/6
IPS-12/2 mice [88] and C57BL/6-Igh-Jtm1Cgn/J mice (JHT,
mice homozygous for the Igh-Jtm1Cgn targeted mutation fail to
produce functional B cells) [55,89] were bred under specific
pathogen-free conditions at the central animal facility of the Paul-
Ehrlich Institute. For experimental work, mice were housed in an
ISOcage unit (Tecniplast, Germany) and had free access to food
and water. All animal experiments were handled in compliance
with the German regulations for animal experimentation (Animal
Welfare Act).
Immunization experiments
Intradermal (i.d.) vaccination was performed by tail scarification
as described elsewhere [41]. Briefly, 10 ml of virus suspension
containing 106 PFU VACV Elstree was deposited on the mouse
skin at the tail base. The skin was then scratched through the
droplet with the tip of a 26-gauge needle (Braun, Melsungen,
Germany) to allow virus uptake. For intramuscular (i.m.)
vaccination, 50 ml of virus suspension containing 108 PFU of
MVA or PBS as a mock control were injected into the right hind
leg. Intranasal (i.n.) immunization was performed as described
elsewhere [24,43]. Briefly, mice were anesthetized by intraperito-
neal (i.p.) injection with 1 mg ketamine and 0.04 mg xylazine per
10 g body weight and instilled i.n. with 30 ml of virus suspension
containing 108 PFU of MVA. In all experiments inoculations of
corresponding amounts of PBS were used as controls (mock
vaccine).
Challenge experiments
Mice were anesthetized by intraperitoneal (i.p.) injection with
1 mg ketamine and 0.04 mg xylazine per 10 g body weight and
infected by i.n. inoculation with 200 PFU (,36LD50) ECTV virus
suspension as described previously [43]. Signs of illness, weight loss
and survival were monitored daily for at least three weeks.
Depletion of specific subsets of immune cells
Mice were depleted of CD4+ T cells, CD8+ T cells, or NK cells
by i.p. administration of mouse monoclonal antibodies purchased
from Harlan Bioproducts, Indianapolis, USA. CD4+ T cells were
depleted by applying 500 mg of anti-CD4 clone GK1.5 antibody
[90] on days 28, 26, 23, 22, and 21 prior to immunization on
day 0. CD8+ T cell depletion was performed by administration of
100 mg anti-CD8 clone 2.43 antibody [91] on days 22 and 21
prior to immunization on day 0. Depletion of both CD4+ and
CD8+ T cells was achieved by combining the two described
applications of GK1.5 and 2.43 antibodies. NK cells were depleted
with an anti-NK1.1 clone PK136 antibody [92] applying 300 mg
of antibody on days 22 and 21 prior to immunization on day 0.
Successful depletion of immune cells was confirmed by flow
cytometric analysis of spleen cells from antibody treated animals
on days 0 and 7 post immunization.
Adoptive T cell transfer
Spleens were isolated from euthanized C57BL/6 mice in pre-
warmed RPMI medium enriched with 10% fetal calf serum.
Single cell suspensions were obtained by passing cells through a
nylon mesh (Nybolt PA-150/38, Franz Eckert GmBH, Germany)
and erythrocytes were lysed by treatment with Red blood cell lysis
buffer (Sigma Aldrich, Taufkirchen, Germany). Subsequently,
cells were washed with medium and passed through a 70 mm
filter (Filcon, BD Biosciences, Heidelberg, Germany) and again
washed with medium. For isolation of untouched T cells the
spleen cell suspension was magnetically labeled using the Pan T
Cell Isolation Kit (Miltenyi, Bergisch Gladbach, Germany) and
isolated using an autoMacsTM separator according to the
manufacturer’s protocol. Purity of the isolated T cells was
confirmed by flow cytometry. Rag-12/2 mice were injected
intravenously with 26107 CD3+ cells per mouse two days before
immunization and the engraftment was confirmed by FACS
analysis of blood samples on days 4, 9, 11, 15, 21 and 37 after
administration.
Histopathology
Lungs from sacrificed mice were fixed by instilling formalde-
hyde solution (4%, pH 7.2) through the trachea. Inflated lungs and
livers were removed and fixed in phosphate buffered formalin.
Tissues were embedded in paraffin and sections (4 mm) were
stained with hematoxylin and eosin before being evaluated by light
microscopy.
Bronchoalveolar lavages (BAL)
Lungs from sacrificed mice were inflated three times with 0.7 ml
PBS using a stainless steel buttoned cannula (ACUFIRM, Ernst
Kratz KG Nadelfabrik, Germany 1428 LL). Pooled fluids (n = 3)
were collected and cells were harvested by low-spin centrifugation
for antibody staining and FACS analysis. The cell-free fluids of the
first instillation were collected and stored at 280uC for further
analysis to detect cytokines and antibodies by ELISA.
Flow cytometry
Approximately 105 cells were stained in 50 ml PBS supple-
mented with 3% FCS using monoclonal antibodies obtained
from BD Biosciences (Heidelberg, Germany). Monocytes,
neutrophils, dendritic cells, NK cells, B cells, and T cells were
detected using APC-labeled CD11c, PerCP-Cy5.5-labeled
CD11b, PE-Cy7-labeled Gr-1, PE-labeled CD49b, PE-Cy7-
labeled NK1.1, APC-Cy7-labeled B220, PerCp-Cy5.5-labeled
CD3, PE-labeled CD4 and FITC-labeled CD8 antibodies. To
ensure specificity of staining, all staining tests contained an
isotype-matched control antibody. Stained cells were fixed with
PBS supplemented with 0.5% paraformaldehyde and analyzed
with BD LSRII and BD FACSDiva 6.0 software (BD
Biosciences, Heidelberg, Germany).
vaccinated (m) mice served as controls. In all experiments weight loss of individual mice was monitored daily (n = 2 to 6 per group). +indicate the
individual time of death. Error bars indicate SEMs, and the numbers of surviving/total animals are given in parentheses. Data are representative of two
similar experiments. Statistical significance of differences between groups is indicated by * for p-value,0.05, ** for p-value,0.01 and *** for p-
value,0.001.
doi:10.1371/journal.ppat.1002557.g008
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Analysis of antigen-specific CD8+ T cells by intracellular
cytokine staining
Splenocytes or BAL cells from vaccinated C57BL/6 mice were
stimulated for 5 h with VACV-specific peptide B8R20–27 (TSYK-
FESV) [48] or control peptide LacZ876 (TPHPARIGL) [93]
purchased from Thermo Fisher Scientific GmbH (Ulm, Germany)
in the presence of GolgiStopTM (BD Biosciences, Heidelberg,
Germany). Cells were blocked with anti-CD16/CD32-Fc-Block
(BD Biosciences) and surface markers were stained with PacBlue-
conjugated anti-CD8 (BD Biosciences) and APC-conjugated anti-
CD62L (BD Biosciences, Heidelberg, Germany) in the presence of
Fc-Block (BD biosciences, Heidelberg, Germany) and washed
twice with PBS containing 3% FCS. Intracellular cytokine staining
for IFN-c production was performed with FITC anti–IFN-c (BD
Biosciences, Heidelberg, Germany) using the Cytofix/Cytoperm
kit (BD Biosciences, Heidelberg, Germany) according to the
manufacturer’s recommendations. Data were acquired in a BD
LSRII flow cytometer and analyzed with BD FACSDiva 6.0
software (BD Biosciences, Heidelberg, Germany).
Measurement of cytokines in BAL fluids
Supernatants of the first BAL instillations were collected and
pooled from 3 mice. Detection of different cytokines used
undiluted BAL fluids for ELISA in triplicates. Measurement of
interleukin-6 (IL-6) used a Quantikine ELISA Kit purchased from
R&D Systems (Wiesbaden-Nordenstadt, Germany). ELISA for
detecting interferon-a (IFN-a) was purchased from PBL Inter-
feronSource (distributed by tebu-bio GmbH, Offenbach, Ger-
many). Assays were performed according to manufacturer’s
instructions and repeated at least three times.
Measurement of vaccinia virus specific antibodies by
ELISA
ELISA plates (MaxiSorp 96-well flat-bottom, Nunc, Wiesbaden,
Germany) were coated with sucrose gradient-purified MVA (at a
protein concentration of 1 mg/ml) for 3 h at 37uC and overnight at
4uC. The plates were blocked with PBS containing 0.05% Tween
20 and 10% fetal calf serum for 60 min at 37uC. BAL fluids were
incubated for 60 min at 37uC, washed five times with PBS, and
then incubated for 30 min with a goat anti-mouse IgG conjugated
to horseradish peroxidase (HRP) (Kirkegaard & Perry Laborato-
ries, Gaithersburg USA) (diluted 1:2000 in PBS). After five washes,
the plates were incubated with OPD substrate (Sigma, Tauf-
kirchen, Germany) at room temperature for 5–10 min. The
optical density was measured immediately after addition of stop
solution (0.5 M sulfuric acid) at a wavelength of 490 nm [94].
Reverse transcriptase-PCR (RT-PCR)
RNA isolation and amplification of human GAPDH cDNA
were performed as described [95] using 26 amplification cycles.
Similarly, amplification of murine GAPDH cDNA was performed
with the sense primer 59-GAC AAC TCA CTC AAG ATT GTC
AG-39 and the antisense primer 59-GTA GCC GTA TTC ATT
GTC ATA CC-39, resulting in a product size of 540 bp.
Amplification of VACV B8R gene (GenBank accession no.
AY603355) was undertaken using the sense primer 59-TAA
AAA TTA TGG CAT CAA GAC G-39 and the antisense primer
59-ACA TCT TCT TTG GAT CTA ATT GC-39, resulting in a
product size of 495 bp for MVA, and 540 bp for VACV strain
Elstree. The MVA E3L gene orthologue has been amplified using
the sense primer 59-TTA CTA GGC CCC ACT GAT TC-39 and
the antisense primer 59-GTT CTG ACG CAG AGA TTG TG-
39, resulting in a product size of 406 bp. Primer pairs were
designed using Primer3 software [96]. All oligonucleotides were
synthesized by Eurofins MWG Operon GmbH (Ebersberg,
Germany). PCR products were run on a 1.5% agarose gel and
stained with GelRed purchased from MoBiTec (Go¨ttingen,
Germany). Gel pictures acquired by a CCD camera were analyzed
using the Photo-Capt 12.4 software (Vilber Lourmat, Eberhard-
zell, Germany).
Statistical analysis
Statistical comparison of different groups of mice was performed
as means of the area under the weight curve (AUC) in percent of
individual weight at baseline. The AUC was additionally weighted
with the length of the observation period (usually day of challenge
(day 0) until day 22, or the day the animal died). The differences
between vaccination groups were analyzed with a one-factorial
analysis of variance model. For multiple comparisons p-values
were adjusted with the Bonferroni method. The statistical
evaluation was performed with SAS/STAT software, version
9.2, SAS System for Windows. For statistical significant results the
following convention was used: * – p-value,0.05, ** – p-
value,0.01 and *** – p-value,0.001.
Supporting Information
Figure S1 Intranasal immunization with MVA induces peri-
bronchiolar and perivascular infiltrate of leukocytes in the lung.
Histopathological examination of lungs from C57BL/6 mice after
intranasal (i.n.) inoculation with mock vaccine (top panel) or
108 PFU MVA (lower panel). At 48 hours after inoculation
inflated lungs were fixed with 4% formalin and embedded in
paraffin. Sections were stained with hematoxilin and eosin (HE).
Overview images demonstrate the extent of the infiltrate
developing after MVA inoculation.
(TIF)
Figure S2 Intranasal immunization with MVA induces peri-
bronchiolar and perivascular infiltrate of leukocytes in the lung.
Histopathological examination of lungs from C57BL/6 mice after
intranasal (i.n.) inoculation with mock vaccine (top panel) or
108 PFU MVA (lower panel). At 48 hours after inoculation
inflated lungs were fixed with 4% formalin and embedded in
paraffin. Sections were stained with hematoxilin and eosin (HE).
Images at higher magnification show the presence of neutrophils
and macrophages.
(TIF)
Figure S3 Rapid infiltration of innate immune cells after i. n.
immunization with MVA. The bronchoalveolar lavage (BAL) data
are representative of two independent experiments. Mice (n = 3)
were immunized with either mock vaccine (PBS) (#) or MVA
(16108 PFU) (N) and BAL performed at the indicated time points.
(A) Pooled BAL cells were analyzed by FACS to detect monocytes
(CD11b+), (B) dendritic cells (DC) (CD11b+ CD11c+), (C)
neutrophils (CD11b+ Gr-1high) and (D) natural killer (NK) cells
(CD32 NK1.1+). Total cell numbers are shown.
(TIF)
Figure S4 B8R gene products are expressed at equal levels by
MVA and conventional VACV strain Elstree/Lister. (A) Sche-
matic representation of the B8R coding sequences (CDS) in the
genomes of VACV Elstree/Lister (CDS 257) and MVA (CDS
176). The gene products are depicted by grey arrows and the sites
of truncations within the MVA B8 protein are shown by white
boxes. A hatched box indicates the position of the conserved
peptide epitope B8R20–27. (B) MVA or VACV Elstree/Lister
specific B8R gene products were analyzed by RT-PCR. NIH 3T3
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cells were infected with virus at an MOI of 20 and total RNA was
prepared at 2 and 4 hours post infection (h p.i.). RNA from mock
infected cells and GAPDH specific RT-PCR served as controls.
(TIF)
Figure S5 Rapid activation of innate immune responses after i.
n. immunization with MVA. The bronchoalveolar lavage (BAL)
data are representative of two independent experiments. Mice
(n = 3) were immunized with either mock vaccine (PBS) (%) or
MVA (16108 PFU) (&) and BAL performed at the indicated time
points. (A) Pooled BAL fluids were analyzed for interferon-a (IFN-
a), and (B) interleukin-6 (IL-6) by ELISA.
(TIF)
Figure S6 Efficient depletion of NK cells, CD8+, and CD4+ T
cells at the time point of immunization. Mice were depleted of
CD4+ T cells, CD8+ T cells, and NK cells by intraperitoneal (i.p.)
administration of mouse monoclonal antibodies. Spleen cells were
stained for different cell surface markers and analyzed by FACS.
The percentage of (A) NK cells (CD32, NK1.1+, CD49b+), (B)
CD8+ T cells (CD3+, CD8+) and (C) CD4+ T cells (CD3+,
CD4+) from antibody treated mice was compared to untreated
mice.
(TIF)
Figure S7 Protective immunization is independent of the
presence of B cells. B cell-deficient JHT mice were i.n. immunized
with MVA (#) two days before 36LD50 ECTV challenge. Mock-
challenged (&) and mock-vaccinated (m) mice served as controls.
In all experiments weight loss of individual mice was monitored
daily (n = 2 to 3 per group). +indicate the individual time of death.
Error bars indicate SEMs, and the numbers of surviving/total
animals are given in parentheses.
(TIF)
Figure S8 C57BL/6 mice and B cell-deficient JHT mice mount
comparable VACV specific T cell responses. At 7 days after MVA
immunization spleen cells from individual C57BL/6 (wt) (n = 6)
mice or B-cell deficient JHT mice (n = 5) were stimulated with
VACV specific peptide B8R20–27 and subsequently CD8+
CD62Llow T cells were analyzed by intracellular cytokine staining
and FACS for gamma interferon expression (IFN-y+).
(TIF)
Figure S9 Heat-inactivated MVA vaccine does not protect from
morbidity and mortality following ECTV challenge. (A) C57BL/6
mice were i.m. immunized with MVA (108 PFU) (n = 5) or heat-
inactivated MVA (corresponding to 108 PFU) (n = 5) two days
before 36LD50 ECTV challenge. Mock-challenged (&) (n = 3)
and mock-vaccinated (m) (n = 5) mice served as controls. In all
experiments weight loss of individual mice was monitored daily
(n = 3 to 5 per group). The data shown are representative for two
similar experiments. +indicate the individual time of death. Error
bars indicate SEMs, and the numbers of surviving/total animals
are given in parentheses. Statistical significance of differences
between groups is indicated by * for p-value,0.05, ** for p-
value,0.01 and *** for p-value,0.001. (B) Confirmation of MVA
inactivation. Heat-treatment (60uC for 4 hours) of MVA vaccine
preparation prevents activation of viral early gene transcription.
Human THP-1 cells were infected with MVA or heat-treated
MVA (corresponding to an MOI of 4) and incubated for 6 h at
37uC. Total RNA was isolated from infected and mock-infected
cells, and analyzed by RT-PCR using specific oligonucleotide
primers for the products of VACV early gene E3L and human
GAPDH.
(TIF)
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